FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Paranovus Entertainment Technology Ltd. Stock AnalysisComprehensive stock analysis for Paranovus Entertainment Technology Ltd. (PAVS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPAVS
PAVS
Paranovus Entertainment Technology Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PAVS
Home🔹Stocks🔹Paranovus Entertainment Technology Ltd.

Paranovus Entertainment Technology Ltd.

🇺🇸PAVS•NASDAQ

Paranovus Entertainment Technology Ltd.

🇺🇸PAVS•NASDAQ
Market cap
$3.86M
Sentiment

Your view on PAVS

Mkt Cap
$3.86M
Sentiment
Your view
PAVS
Paranovus Entertainment Technology Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PAVS
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Paranovus Entertainment Technology Ltd.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Xiaoyue Zhang
Headquarters
No. 11, Dongjiao East Road, New York City, CN
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Xiaoyue Zhang
Headquarters
No. 11, Dongjiao East Road, New York City, CN
Description

Paranovus Entertainment Technology Ltd. engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally.

The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids.

It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures.

In addition, the company provides secure transaction environment, automobile procurement, and financial services for automobile manufacturers under the Taochejun automobile sales platform. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand.

The company was formerly known as Happiness Development Group Limited and changed its name to Paranovus Entertainment Technology Ltd. in March 2023. Paranovus Entertainment Technology Ltd. was founded in 2004 and is headquartered in Nanping, the People's Republic of China.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Paranovus Entertainment Technology Ltd., and the rating behind it. PAVS last traded at $4.50; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Paranovus Entertainment Technology Ltd.. Starting points for Paranovus Entertainment Technology Ltd.: EPS -$7948.70, beta -0.14 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Paranovus Entertainment Technology Ltd.. Paranovus Entertainment Technology Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Paranovus Entertainment Technology Ltd.. Trailing twelve-month EPS for Paranovus Entertainment Technology Ltd. stands at -$7948.70. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Paranovus Entertainment Technology Ltd.. Paranovus Entertainment Technology Ltd. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Paranovus Entertainment Technology Ltd. valued side by side against its closest peers. Paranovus Entertainment Technology Ltd. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Paranovus Entertainment Technology Ltd., and how their positions are changing. At a $3.9M market value, institutional positions materially move Paranovus Entertainment Technology Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Paranovus Entertainment Technology Ltd. executives and directors. Shares of Paranovus Entertainment Technology Ltd. have traded between $0.43 and $1.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Paranovus Entertainment Technology Ltd.. Paranovus Entertainment Technology Ltd. is a $3.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Paranovus Entertainment Technology Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Paranovus Entertainment Technology Ltd.. Coverage tracks Paranovus Entertainment Technology Ltd. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • BNKK — Bonk, Inc.
  • BOF — BranchOut Food Inc.
  • COOT — Australian Oilseeds Holdings Limited Ordinary Shares
  • LSF — Laird Superfood, Inc.
  • NCRA — Nocera, Inc.
  • RYET — Ruanyun Edai Technology Inc. Ordinary shares

More Medical - Pharmaceuticals companies

  • TSUSF — Tsuruha Holdings Inc.
  • UPPR — Upper Street Marketing Inc.
  • VIAP — VIA Pharmaceuticals, Inc.
  • WPHM — Winston Pharmaceuticals, Inc.
  • WUHN — Wuhan General Group (China), Inc.
  • NEUN — Neurogenesis, Inc.
  • NEXI — NexImmune, Inc.
  • NSRX — Nasus Pharma Ltd.
  • NUNZ — Nunzia Pharmaceutical Company
  • OMHE — Omni Health, Inc.
  • ORXOF — Orexo AB (publ)
  • ORXOY — Orexo AB (publ)

News

Latest Market News